Form 4: GoodRx Director Douglas Hirsch Receives Stock Units
Statement of Changes in Beneficial Ownership
Director Douglas Hirsch was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.
Summary
- Douglas Hirsch, a Director at GoodRx Holdings, Inc., acquired 4,642 deferred stock units on May 27, 2026.
- Each unit represents a contingent right to receive one share of Class A common stock.
- The units vest 2% on May 31, 2026, with the remaining 98% vesting in equal monthly installments over the following 7 months.
- Settlement of these units is scheduled for December 31, 2029, or upon specific events such as separation from service or a change in control.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation that does not signal a change in company strategy or financial health.
Positives
- The grant aligns the director's long-term interests with those of shareholders through equity-based compensation.
Negatives
- None identified in this filing.
Risks
- Vesting is subject to the director's continued service through the applicable dates.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure of director compensation, which is standard practice for publicly traded companies to ensure transparency regarding insider equity holdings.
Comparison to Industry Standards
- The use of deferred stock units for director compensation is consistent with standard corporate governance practices for U.S. technology and healthcare companies.
- The vesting schedule is typical for retaining board members and aligning their incentives with long-term company performance.
Related Party Transactions
- The filing discloses holdings by various Grantor Retained Annuity Trusts (GRATs) associated with Douglas Hirsch and his spouse, Chona Hirsch.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation grant.
Next Steps
- Vesting of 2% of the units on May 31, 2026.
- Continued monthly vesting of the remaining units over the subsequent 7 months.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the earliest transaction involving the acquisition of deferred stock units. |
| 05/31/2026 | Initial vesting date for 2% of the granted deferred stock units. |
| 12/31/2029 | Scheduled settlement date for the deferred stock units. |
Keywords
GoodRx, GDRX, Form 4, Director Compensation, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.